Title | Radiation protection and restoration by the synthetic 163-171 nonapeptide of human interleukin 1 beta. |
---|---|
Publication Type | Articolo su Rivista peer-reviewed |
Year of Publication | 1991 |
Authors | Frasca, D., Baschieri Selene, Boraschi D., Tagliabue A, and Doria G. |
Journal | Radiation research |
Volume | 128 |
Pagination | 43-7 |
Date Published | 1991 Oct |
ISSN | 0033-7587 |
Keywords | Adjuvants, Animals, Dose-Response Relationship, Drug, Experimental, Female, Humans, Immunologic, Interleukin-1, Interleukin-1beta, male, Mice, Peptide Fragments, Radiation Injuries, Radiation-Protective Agents, Recombinant Proteins |
Abstract | We have previously reported that the synthetic nonapeptide VQGEESNDK, position 163-171 of human interleukin 1 (IL-1 beta), when injected in immunodepressed mice, shows immunorestorative activity similar to that of the whole protein, but with no IL-1-like inflammatory effects [Frasca et al., J. Immunol. 141, 2651-2655 (1988)]. In the present study we have compared the protective and restorative activities of the nonapeptide and human recombinant (hur) IL-1 beta on the survival of lethally irradiated mice. When mice were given a single injection of different doses of the nonapeptide or hurIL-1 beta 20 h before total-body irradiation, both molecules increased the percentage survival of mice exposed to 750 or 850 cGy, but not to 950 cGy. The nonapeptide, however, is less effective than hurIL-1 beta and displays a different dose-response relationship, suggesting that the two molecules act through different radioprotective pathways. When mice were injected with the nonapeptide or hurIL-1 beta immediately after exposure to 850 cGy, the percentage survival was also increased but restoration was lower than protection in both cases. The nonapeptide was also less effective than hurIL-1 beta in restoration, but the two molecules displayed a comparable dose-response relationship as if they shared similar mechanisms. These findings indicate that the 163-171 nonapeptide is able to protect from lethal radiation injury and to restore viability. The nonapeptide appears less effective than hurIL-1 beta but does not exhibit the IL-1-like side effects of the whole molecule. |
Citation Key | 5422 |